Controlled Human Infection Model - Fast Track to HCV Vaccine?

Affiliations

¹ From the Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda (T.J.L.), and the Division of Infectious Diseases, Johns Hopkins University, Baltimore (A.C.) - both in Maryland; the Toronto Centre for Liver Disease, Toronto General Hospital, University of Toronto, Toronto (J.J.F.); and the Laboratory of Virology and Infectious Disease, Rockefeller University, New York (C.M.R.).

T Jake Liang et al. N Engl J Med. 2021.

. 2021 Sep 23;385(13):1235-1240.

doi: 10.1056/NEJMsb2109093.

¹ From the Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda (T.J.L.), and the Division of Infectious Diseases, Johns Hopkins University, Baltimore (A.C.) - both in Maryland; the Toronto Centre for Liver Disease, Toronto General Hospital, University of Toronto, Toronto (J.J.F.); and the Laboratory of Virology and Infectious Disease, Rockefeller University, New York (C.M.R.).

No abstract available

References

1. Liang TJ, Ward JW. Hepatitis C in injection-drug users — a hidden danger of the opioid epidemic. N Engl J Med 2018;378:1169–71. - PMC - PubMed
1. Liang TJ. Current progress in development of hepatitis C virus vaccines. Nat Med 2013;19:869–78. - PMC - PubMed
1. Bailey JR, Barnes E, Cox AL. Approaches, progress, and challenges to hepatitis C vaccine development. Gastroenterology 2019;156:418–30. - PMC - PubMed
1. Burm R, Collignon L, Mesalam AA, Meuleman P. Animal models to study hepatitis C virus infection. Front Immunol 2018;9:1032. - PMC - PubMed
1. Page K, Melia MT, Veenhuis RT, et al. Randomized trial of a vaccine regimen to prevent chronic HCV infection. N Engl J Med 2021;384:541–9. - PMC - PubMed